Literature DB >> 22935805

Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity'?

Giovanni Lentini.   

Abstract

Mesh：

Year:  2012        PMID： 22935805     DOI： 10.1038/nrd3503-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

1.  Racemates versus enantiomers in drug development: dogmatism or pragmatism?

Authors:  B Testa; W F Trager
Journal:  Chirality       Date:  1990       Impact factor: 2.437

Review 2.  Enantioselective aspects of drug action and disposition: therapeutic pitfalls.

Authors:  F Jamali; R Mehvar; F M Pasutto
Journal:  J Pharm Sci       Date:  1989-09       Impact factor: 3.534

3.  The relation between biological activity and the degree of resolution of optical isomers.

Authors:  R B Barlow; F M Franks; J D Pearson
Journal:  J Pharm Pharmacol       Date:  1972-10       Impact factor: 3.765

Review 4.  Biological significance of the enantiomeric purity of drugs.

Authors:  B Waldeck
Journal:  Chirality       Date:  1993       Impact factor: 2.437

Review 5.  Minimum information about a bioactive entity (MIABE).

Authors:  Sandra Orchard; Bissan Al-Lazikani; Steve Bryant; Dominic Clark; Elizabeth Calder; Ian Dix; Ola Engkvist; Mark Forster; Anna Gaulton; Michael Gilson; Robert Glen; Martin Grigorov; Kim Hammond-Kosack; Lee Harland; Andrew Hopkins; Christopher Larminie; Nick Lynch; Romeena K Mann; Peter Murray-Rust; Elena Lo Piparo; Christopher Southan; Christoph Steinbeck; David Wishart; Henning Hermjakob; John Overington; Janet Thornton
Journal:  Nat Rev Drug Discov       Date:  2011-08-31       Impact factor: 84.694
  5 in total
  1 in total

1.  COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.

Authors:  Giovanni Lentini; Maria Maddalena Cavalluzzi; Solomon Habtemariam
Journal:  Molecules       Date:  2020-04-16       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.